



Eye Cancer Insights | Executive Overview

5000

Total Cases

61

Avg Survival Time (Months)

Lymphoma

Dominant Type

45

Average Age

Australia

Max Cases

Completed

Max Surgery Status

Overview





Treatment Effectiveness

Genetic & Family History

Patient Demographics

Forecasting

Patient Details

Developed By:
Naseef
Mohammed
Ansaf

Gender All

Year All

Cancer Types
Lymphoma
Melanoma
Retinoblastoma

Country
Australia
Brazil
Canada
France
Germany
India
Japan
South Africa
UK
USA



Eye Cancer Insights | Treatment vs Outcome Analysis

Overview

Treatment Effectiveness







Genetic & Family History

Patient Demographics

Forecasting

Patient Details

Developed By:
Naseef
Mohammed
Ansaf





Eye Cancer Insights | Genetic & Family History Impact

Overview

Treatment Effectiveness

Genetic & Family History


Patient Demographics

Forecasting


Patient Details

Developed By:
Naseef
Mohammed
Ansaf

Genetic Marker Distribution




Family History Presence Among Patients



Genetic Marker vs Outcome Matrix

Genetic Markers	Active	Deceased	In Remission
BRAF Mutation	825	833	845
None	790	877	830

Genetic Markers by Cancer Type



Survival Trends by Family History



Genetic Markers

- BRAF Mutation
- None

Outcome Status

- Active
- Deceased
- In Remission

Surgery Status

- Completed
- Not Completed

Treatment Type

- Chemotherapy
- Radiation
- Surgery



Eye Cancer Insights | Patient Demographics Insights

Overview

Treatment Effectiveness



Genetic & Family History

Patient Demographics

Forecasting



Patient Details

Developed By:
Naseef
Mohammed
Ansaf



Country

- Australia
- Brazil
- Canada
- France
- Germany
- India
- Japan
- South Africa
- UK
- USA



Age Group

- 1-20
- 21-30
- 31-40
- 41-50
- 51-60
- 60+

Gender

- Female
- Male
- Other



Eye Cancer Insights | Forecasting

Overview

Treatment Effectiveness

Genetic & Family History

Patient Demographics

Forecasting


Patient Details

Developed By:
Naseef
Mohammed
Ansaf

Survival Trends by Family History



Forecasting: Survival Trends By Family History (2025-2030)





Eye Cancer Insights | Patient Details

Overview

Treatment Effectiveness

Genetic & Family History

Patient Demographics

Forecasting

Patient Details

Developed By:
Naseef
Mohammed
Ansaf

Patient ID	Year	Month	Day	Outcome Status	Country	Cancer Type	Family History	Gender	Genetic Markers	Laterality	Stage at Diagnosis
PID00001	2019	January	25	Deceased	UK	Retinoblastoma	Yes	Female	None	Left	Stage IV
PID00002	2021	October	21	In Remission	Japan	Retinoblastoma	Yes	Other	None	Right	Stage III
PID00003	2021	March	12	In Remission	UK	Retinoblastoma	No	Male	BRAF Mutation	Bilateral	Stage IV
PID00004	2021	May	10	Active	Canada	Melanoma	No	Male	None	Right	Stage II
PID00005	2019	November	24	In Remission	USA	Lymphoma	Yes	Other	BRAF Mutation	Left	Stage I
PID00006	2023	January	13	Active	UK	Retinoblastoma	Yes	Other	BRAF Mutation	Bilateral	Stage III
PID00007	2019	June	5	Deceased	Australia	Lymphoma	No	Other	BRAF Mutation	Right	Stage I
PID00008	2024	October	23	In Remission	Germany	Retinoblastoma	Yes	Other	BRAF Mutation	Bilateral	Stage III
PID00009	2021	June	9	In Remission	USA	Retinoblastoma	Yes	Other	None	Right	Stage I
PID00010	2022	December	29	In Remission	South Africa	Lymphoma	Yes	Male	None	Right	Stage IV
PID00011	2019	May	16	Deceased	UK	Lymphoma	Yes	Other	None	Bilateral	Stage II
PID00012	2024	August	22	Deceased	UK	Lymphoma	Yes	Female	BRAF Mutation	Right	Stage IV
PID00013	2019	April	8	In Remission	Brazil	Retinoblastoma	Yes	Other	None	Right	Stage IV
PID00014	2024	March	4	Deceased	Brazil	Lymphoma	Yes	Male	BRAF Mutation	Right	Stage I
PID00015	2024	September	5	Active	Canada	Retinoblastoma	No	Other	BRAF Mutation	Left	Stage I
PID00016	2023	April	5	Deceased	France	Lymphoma	No	Other	None	Bilateral	Stage I
PID00017	2023	February	1	Deceased	USA	Lymphoma	No	Male	None	Bilateral	Stage II
PID00018	2023	September	24	Active	France	Retinoblastoma	Yes	Male	BRAF Mutation	Bilateral	Stage I
PID00019	2020	April	24	Active	France	Lymphoma	No	Male	BRAF Mutation	Right	Stage II
PID00020	2023	October	4	Active	Australia	Melanoma	No	Other	None	Right	Stage IV
PID00021	2019	October	20	In Remission	Japan	Melanoma	Yes	Male	None	Left	Stage II